Publication | Closed Access

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

Lymphoid NeoplasiaOncologyRefractory HodgkinPediatric HematologyCancer TreatmentMedicineRadiation OncologyCancer ResearchPhase 1–2Brentuximab Vedotin